| Literature DB >> 30333299 |
Yusuke Nakade1, Yasunori Iwata2,3, Kengo Furuichi3,4, Masashi Mita5, Kenji Hamase6, Ryuichi Konno7, Taito Miyake3, Norihiko Sakai3, Shinji Kitajima3, Tadashi Toyama3, Yasuyuki Shinozaki3, Akihiro Sagara3, Taro Miyagawa3, Akinori Hara3, Miho Shimizu3, Yasutaka Kamikawa3, Kouichi Sato3, Megumi Oshima3, Shiori Yoneda-Nakagawa3, Yuta Yamamura3, Shuichi Kaneko8, Tetsuya Miyamoto9, Masumi Katane9, Hiroshi Homma9, Hidetoshi Morita10, Wataru Suda11,12, Masahira Hattori12,13, Takashi Wada1,3.
Abstract
Gut microbiota-derived metabolites play important roles in health and disease. D-amino acids and their L-forms are metabolites of gut microbiota with distinct functions. In this study, we show the pathophysiologic role of D-amino acids in association with gut microbiota in humans and mice with acute kidney injury (AKI). In a mouse kidney ischemia/reperfusion model, the gut microbiota protected against tubular injury. AKI-induced gut dysbiosis contributed to the altered metabolism of D-amino acids. Among the D-amino acids, only D-serine was detectable in the kidney. In injured kidneys, the activity of D-amino acid oxidase was decreased. Conversely, the activity of serine racemase was increased. The oral administration of D-serine mitigated the kidney injury in B6 mice and D-serine-depleted mice. D-serine suppressed hypoxia-induced tubular damage and promoted posthypoxic tubular cell proliferation. Finally, the D-serine levels in circulation were significantly correlated with the decrease in kidney function in AKI patients. These results demonstrate the renoprotective effects of gut-derived D-serine in AKI, shed light on the interactions between the gut microbiota and the kidney in both health and AKI, and highlight D-serine as a potential new therapeutic target and biomarker for AKI.Entities:
Keywords: Amino acid metabolism; Microbiology; Nephrology
Mesh:
Substances:
Year: 2018 PMID: 30333299 PMCID: PMC6237464 DOI: 10.1172/jci.insight.97957
Source DB: PubMed Journal: JCI Insight ISSN: 2379-3708